Market Place
Sourcing Support
Xenetic Biosciences Reports Q1 2025 Financial Results and Update
14 May 2025 //
ACCESSWIRE
Xenetic Biosciences releases virtual investor Segment
09 Apr 2025 //
ACCESSWIRE
Xenetic Biosciences Partner Enters Clinical Study for DNase
26 Mar 2025 //
ACCESSWIRE
Xenetic Biosciences Reports 2024 Financial Results
19 Mar 2025 //
ACCESSWIRE
Xenetic Bio Shows Positive Preclinical Data Potential of DNase I
13 Mar 2025 //
ACCESSWIRE
Xenetic Biosciences Abstract Accepted for SITC 2025 Meeting
27 Feb 2025 //
ACCESSWIRE
Xenetic Bio Partners with PeriNess for DNase I Oncology Trials
05 Dec 2024 //
ACCESSWIRE
Xenetic Bio Presents Preclinical Data on DNase I and CAR T Cells
21 Nov 2024 //
PHARMAWEB
Xenetic Engages Jonathan Spicer for Advancement of DNase Oncology Platform
16 Nov 2022 //
ACCESSWIRE
Xenetic Biosciences Announces Signing of Patent Collaboration VolitionRx & CLS
11 Oct 2022 //
ACCESSWIRE
Xenetic Biosciences Appoints Allan Tsung to its Scientific Advisory Board
04 Oct 2022 //
BIOSPACE
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results
12 Aug 2022 //
ACCESSWIRE
Catalent Enters Clinical Manufacturing Deal with Xenetic Bioscienes
08 Jul 2022 //
CONTRACTPHARMA
Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent
09 Sep 2021 //
BIOSPACE
Xenetic Biosciences Reports Second Quarter 2021 Financial Results
13 Aug 2021 //
PRESS RELEASE
Xenetic Announces Positive Data from Partner’s Pivotal Phase 3 Trial
09 Dec 2020 //
XENETICBIO
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.